Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions
Stopped early · Phase 2
Conditions studied: NSCLC, Stage IV, NSCLC Stage IIIB, NSCLC, Stage IIIC, NSCLC, Recurrent, EGFR Exon 20 Insertion Mutation, HER2-activating Mutation, ERBB Fusion, NRG1 Fusion
In brief
Open-label, Phase 2, single treatment arm, 3 cohorts
Key facts
- Study ID
- NCT03805841
- Run by
- Rain Oncology Inc
- People needed
- 41
- Starts
- 2019-03-13
- Expected to finish
- 2021-04-23
- Last updated by the study team
- 2023-06-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- RAIN-701 Study Site — Irvine, California, United States
- Pacific Shores Medical Group — Long Beach, California, United States
- University of California San Francisco, Helen Diller Cancer Center — San Francisco, California, United States
- RAIN-701 Study Site — Aurora, Colorado, United States
- Georgetown University Medical Center — Washington D.C., District of Columbia, United States
- Comprehensive Care and Research Center, Atlanta — Newnan, Georgia, United States
- Northwestern University Feinberg School of Medicine — Chicago, Illinois, United States
- Henry Ford Cancer Institute — Detroit, Michigan, United States
- Providence Cancer Institute — Portland, Oregon, United States
- RAIN-701 Study Site — Pittsburgh, Pennsylvania, United States
- RAIN-701 Study Site — Seattle, Washington, United States
- RAIN-701 Study Site — Toronto, Ontario, Canada
- RAIN-701 Study Site — Hong Kong, Hong Kong
- Hong Kong United Oncology Center — Kowloon, Hong Kong
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.